Association of β2-adrenergic receptor haplotypes with drug response
AssigneeGenaissance Pharmaceuticals
InventorsConnie M. Drysdale, Richard S. Judson, Stephen B. Liggett, Krishnan Nandabalan, Catherine B. Stack, J. Claiborne Stephens
Life of this patent
Estimating the term…
Abstract
Genotypes and haplotypes for thirteen polymorphic sites in the β2-adrenergic receptor (β2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (β2AR) gene, as well as for predicting response to β-agonists, are also disclosed.
Claims10
A diagnostic kit for predicting an individual's bronchodilating response to a β-agonist comprising a set of genotyping oligonucleotides, wherein said set comprises a first oligonucleotide for genotyping PS3, a second oligonucleotide for genotyping PS9 and a third oligonucleotide for genotyping PS11 in the β2AR gene packaged in a container, wherein PS3 is located in the β2AR gene at a nucleotide position corresponding to nucleotide 934 in SEQ ID NO:1, PS9 is located in the β2AR gene at a nucleotide position corresponding to nucleotide 1633 in SEQ ID NO:1, and PS11 is located late in the β2AR gene at a nucleotide position corresponding to nucleotide 1839 in SEQ ID NO;1, wherein each of the first, second and third oligonucleotides is selected from the group consisting of an allele specific oligonucleotide probe, an allele specific oligonucleotide primer, and a primer extension oligonucleotide.
A method for predicting an individual's bronchodilating response to a β-agonist, which comprises
- (a) assigning a β2AR haplotype pair to the individual, wherein the β2AR haplotype pair is selected from the group consisting of haplotype pairs 4/6, 2/2, 2/6, 2/4, and 4/4, which are shown in Table 4;
- and
- (b) using the assigned haplotype pair to predict the individual's bronchodilating response,
- wherein assignment of β2AR haplotype pair 4/6 or 2/2 predicts that the individual will exhibit a greater bronchodilating response than an individual with a β2AR haplotype pair assignment of 2/6, 2/4, or 4/4, assignment of β2AR haplotype pair 2/6 predicts that the individual will exhibit a greater bronchodilating response than an individual with a β2AR haplotype pair assignment of 2/4 or 4/4 and a smaller bronchodilating response than an individual with a β2AR haplotype pair assignment of 4/6 or 2/2, and assignment of β2AR haplotype pair 2/4 or 4/4 predicts that the individual will exhibit no bronchodilating response.
Dependencies are inferred from the claim text.